|
|
Repligen Corporation - Comparative Business Analysis Snapshot
Business Description
Repligen Corporation. The Group's principal activity is to develop novel therapeutics primarily for radiology and neuropsychiatry. It currently sells a line of commercial products based on Protein A, which are used in the production of monoclonal antibodies. The Group manufactures and markets several products based on recombinant forms of Protein A. Its primary customers incorporate its Protein A products into their proprietary monoclonal antibody purification products that they sell directly to the biotechnology and pharmaceutical industry.
Competitor Analysis
This analysis compares Repligen Corporation with three other companies in closely related industry sectors.
The full Comparative Business Report is available to Subscribers or may be purchased individually. The full report generally includes the following sections:
- Sales Analysis: Recent Sales, Sales Growth, Sales per Employee
- Recent Stock Performance
- Company Valuation Ratios: Price/Earnings, Price/Book Value
- Price/Sales and 52 Week Price change
- Dividend Analysis
- Profitability Analysis: Gross Profit Margin, EBITDA Margin
- Earnings Before Extraordinary Items
- Inventory Analysis
- Research and Development Expenses
- Financial Position: Long Term Debt/Equity, Days Accounts Receivable, Days Inventory
- R&D Expenses/Sales
Not the Report you are looking for? Click here for more browsing options.
|
|
|
|
|
